Devoted Health

1.1 Company Identity, Product, and Headquarters

Devoted Health, Inc. is a Delaware-incorporated, Waltham, Massachusetts–based healthcare company that designs and operates an integrated all-in-one Medicare Advantage solution for Americans aged 65 and older. The company was incorporated under the name Orinoco Health, Inc. and filed its first SEC Form D on October 20, 2017, with its registered principal office listed at 15 Temple Street, Newton, MA. The operational headquarters has since moved to the historic Waltham Watch Company building in Waltham, MA—a location the co-founders have cited as symbolic of their mission to carry on a legacy of American innovation. The legal entity remains Devoted Health, Inc. (CIK 0001719459). The company's product model is built on four integrated layers: (1) Devoted Health Medicare Advantage insurance plans (HMO and PPO) offered to Medicare-eligible beneficiaries in select counties, (2) Devoted Medical—a virtual-first and in-home medical group composed of hundreds of clinical staff (doctors, nurses, and other clinicians) who serve exclusively Devoted Health members at no additional cost, (3) dedicated "Guide" concierges who answer calls within 30 seconds and resolve 90 percent of health questions within a day, and (4) the Orinoco platform—a proprietary software system described by the company as the first modern platform capable of supporting the entirety of payor and healthcare provider operations end-to-end in a highly integrated way. Devoted's value proposition centers on preventing costly acute episodes through intensive preventive and chronic disease management, enabled by the Orinoco platform's real-time care choreography. As of January 30, 2026, Devoted Health serves over 466,000 members across 29 states, representing a 121 percent year-over-year increase. CMS-published star ratings (2026 cycle) show 100 percent of Devoted members in Star-eligible plans enrolled in plans rated 4 Stars or higher on key measures including statin therapy adherence, medication reconciliation, and blood pressure control, with six contracts receiving the top 5-star rating. The company has been recognized on Fast Company's Most Innovative Companies 2024 list and Forbes' America's Best Startup Employers 2024 list. U.S. News & World Report independently rated Devoted Health Medicare Advantage a 4 out of 5 for 2026, noting that roughly 92 percent of plans carry a $0 monthly consolidated premium.[CO001, CO002, CO003, CO004, CO006, CO007]

1.2 Founders, Leadership, and Board Governance

Devoted Health was founded in 2017 by brothers Todd Park and Ed Park, both of whom built their careers at athenahealth, the health-technology company they co-founded (along with Jonathan S. Bush) in 1997. Ed Park served as a long-tenured COO and technical executive at athenahealth before co-founding Devoted, where he serves as CEO and drives day-to-day strategy, product, and operations. Todd Park serves as Executive Chairman; prior to Devoted, he co-founded Castlight Health in 2008, served as Chief Technology Officer of the U.S. Department of Health and Human Services (2009–2012), and then as the second US Chief Technology Officer under President Barack Obama (March 2012 – August 2014). Todd Park was also a key figure in the emergency repair of HealthCare.gov in 2013. Their combined background in healthcare technology, government policy, and managed care start-up execution represents an unusually strong founder-market fit for a Medicare Advantage business that relies on data infrastructure and regulatory navigation. The 2017 SEC Form D filing names Ed Park (CEO), Todd Park, Bryan Roberts, Robert Kocher, Kathleen Sebelius, and William Frist as the principal officers and directors at formation. Kathleen Sebelius served as U.S. Secretary of Health and Human Services from 2009 to 2014, providing regulatory insight and HHS network value. William Frist is a practicing physician, former U.S. Senate Majority Leader (2003–2007), and co-founder of Frist Cressey Ventures—Devoted's Series D and subsequent investor—making him both a board member and an aligned capital partner. Bryan Roberts and Robert Kocher are partners at Venrock, the venture firm that led or participated in early financing rounds. Key-person risk is concentrated in Ed Park as the operational CEO and public face of the company and in Todd Park as its technology visionary and government-network anchor. No material leadership changes have been disclosed through the report date; no CFO, COO, or other C-suite additions have been announced in public sources reviewed.[CO011, CO012, CO013, CO014, CO015, CO016]

1.3 Funding History, Valuation, and Investor Base

Devoted Health has raised capital across six named rounds since its 2017 founding, accumulating approximately $2.27 billion in total equity through January 2026 (Sacra estimate; individual round amounts confirmed via primary legal and official sources). The company's funding trajectory reflects initial rapid confidence from top-tier venture investors, a peak valuation of over $12.6 billion at the Series D (2021), and a subsequent valuation plateau—the December 2023 Series E was issued at the same $56.25 per-share price as the Series D, constituting a "flat round" that observers interpreted as reflecting MA sector headwinds rather than enterprise appreciation. The aggregate Series E, ultimately closed at $287 million in two tranches (December 2023 and August 2024), and the 2025–2026 Series F and Series F-Prime ($366 million) together sustained growth capital despite this valuation context. The Series B ($300 million, October 2018) was led by Andreessen Horowitz, with Premji Invest, Uprising, Venrock, and F-Prime Capital participating—the same VC syndicate that would anchor later rounds. The Series D ($1.15 billion, October 2021) was the largest round; Uprising led, SoftBank Vision Fund 2 co-led with its largest single investment, and returning investors (GIC, a16z, Premji, Maverick, Frist Cressey, NextView) were joined by new entrants ICONIQ Growth, General Catalyst, the Base10 Advancement Initiative, and Emerson Collective. Latham & Watkins advised SoftBank Vision Fund 2 and Fenwick & West advised Devoted Health in that transaction. The Series F and Series F-Prime (completed November 2025 and January 2026, respectively) brought in new institutional investors including GV (Google Ventures), Morgan Health (a division of JPMorganChase), Franklin Venture Partners (Franklin Templeton), VanEck, and MIG Private Equity, alongside significant participation from existing investors including Cox Enterprises, Premji Invest, a16z, and General Catalyst. No secondary sales, debt financing, or credit facility disclosures have been confirmed in primary sources reviewed for this chapter. The Devoted Health SPV II LLC (CIK 0002078127) filed a Form D in July 2025 for a $33 million private equity fund offering, indicating secondary or co-investment vehicle activity around Devoted Health equity.[CO023, CO024, CO025, CO026, CO027, CO028]

1.4 Milestones, Scale, and Adverse Events

Devoted Health's growth trajectory from formation to January 2026 follows a steep S-curve characteristic of capital-intensive MA startups: roughly five years of platform and footprint construction (2017–2022), followed by rapid member acquisition (2023 to date) enabled by the Orinoco platform's scalability. Key inflection points include the October 2022 expansion to 13 states (from an initial Florida-only launch), the December 2023 CMS recognition of 5-star plans in Florida and Ohio, and the January 2026 announcement of 466,000 members in 29 states—a 121 percent annual growth rate that outpaced most public MA peers. Revenue from regulated health plan subsidiaries grew from approximately $1.9 billion in 2023 to approximately $3.3 billion in 2024, a 69 percent year-over-year increase, based on an Endpoints News analysis of 33 individual state insurance filings. These state filings capture only the regulated plan entities and exclude the Orinoco technology platform costs and Devoted Medical expenses booked at the parent or medical group level—meaning disclosed financials understate the company's full cost base. Operating losses at the plan-subsidiary level were $55.4 million in 2023, though they shrank in 2024. Net income at the plan-subsidiary level turned positive in Q1 2024 ($11 million vs. a $8.9 million loss in Q1 2023), driven partly by investment income. The company has never disclosed consolidated profitability, and its spokesperson confirmed in mid-2024 that it is "building toward profitability." Adverse events include: the May 2025 workforce reduction of approximately 5 percent, coinciding with broader Medicare Advantage sector headwinds from CMS V28 risk-model cuts and continued benefit compression; persistent losses since founding; the flat Series E valuation; and member service concerns discussed in insurance broker community forums. The company's financials as disclosed through state filings are partial and cannot be taken as a complete picture of consolidated performance, a limitation acknowledged by the Endpoints News analysis methodology.[CO036, CO037, CO038, CO039, CO040, CO041]

1.5 Exhibits

2.1 Market Boundary, Inclusions, and Substitutes

Medicare Advantage (Part C) is the private-insurance alternative to traditional fee-for-service (FFS) Medicare. Under the program, CMS pays risk-adjusted monthly capitation to Medicare Advantage Organizations (MAOs) in exchange for covering all Medicare Part A (hospital inpatient), Part B (outpatient and physician), and in most cases Part D (prescription drugs) benefits within a single plan. Enrollees typically pay a plan premium in addition to the standard Part B premium, though many MA plans charge $0 additional premium and return surplus capitation as supplemental benefits—dental, vision, hearing, over-the-counter allowances, and transportation. Plans must maintain an 85% medical loss ratio (MLR) with any excess rebated to CMS to fund these additional benefits. The market boundary excludes three primary alternatives. First, traditional fee-for-service Medicare accounts for the remaining ~45% of Medicare beneficiaries; it is administered directly by CMS without capitation and offers no supplemental benefits. Second, Medicare Supplement (Medigap) plans layer cost-sharing coverage on top of FFS Medicare but do not replace the FFS relationship with CMS; beneficiaries cannot hold both Medigap and MA simultaneously. Third, employer-sponsored retiree coverage—though declining as companies shed retiree health liabilities—remains an alternative for beneficiaries whose former employer still offers subsidized group coverage. Standalone Part D Prescription Drug Plans (PDPs) serve FFS enrollees for drug coverage only and operate outside the MA capitation model entirely. Adjacent markets include Medicaid managed care (D-SNP plans operate at the Medicare-Medicaid intersection), ACA exchange and group commercial health plans (the pipeline from which 65+ age-in to Medicare), and long-term care insurance for the highest-acuity senior population. CMS's risk-adjusted benchmark methodology—which sets per-county capitation rates by multiplying FFS per-capita spending by a quality-adjusted factor—directly couples the MA market boundary to the FFS Medicare program and makes the relative MA-versus-FFS cost ratio a persistent regulatory flashpoint. [CM001, CM002, CM003, CM004, CM005]

2.2 Market Sizing — TAM, SAM, and SOM

Multiple independent data lenses converge on a 2026 total addressable market (TAM) of approximately $490–$530 billion in federal MA expenditures and 34.9–35.5 million enrollees. MedPAC's March 2025 report documents $494 billion in CMS payments to MA plans in 2024, with 33.6 million enrollees representing 54% of Medicare. MedPAC's January 2026 update shows 2025 enrollment reaching 34.9 million (55% penetration), while STAT News reported 35.5 million as of February 1, 2026—a 3% year-over-year gain from 34.4 million in February 2025. USHealthInsights projects CMS MA program spend at approximately $507 billion in 2026. The CMS 2026 Rate Announcement finalized a +5.06% net increase in average payments, totaling approximately $25 billion in additional federal spend with a 9.04% effective growth rate. Enrollment growth has decelerated sharply: from 7–10% annually during 2017–2024, to 3.9% in calendar 2025 (Chartis), to approximately 2.5% for 2026 and just ~1% during the 2025–26 Annual Enrollment Period (Chartis, STAT News). The Congressional Budget Office projects MA penetration will reach 64% of all Medicare beneficiaries by 2034, anchoring a durable long-run growth case. The serviceable addressable market (SAM) for challenger MA carriers such as Devoted Health is the HMO-based and SNP-focused segment: approximately 20–22 million enrollees in managed-care plan designs that favor clinical integration, value-based primary care, and condition-specific care management over broad PPO networks. Within this SAM, the C-SNP and D-SNP subsegments are the highest-growth components, expanding approximately 49% and 10–15% in 2026, respectively. Devoted Health's current serviceable obtainable market (SOM) spans 29 operating states. Devoted more than doubled its enrollment during the 2026 AEP—from approximately 210,000 to roughly 470,000 members—and CEO Ed Park confirmed approximately 500,000 members served as of early 2026, making Devoted one of a handful of national challenger carriers by Milliman's classification. [CM006, CM007, CM008, CM009, CM010, CM011]

2.3 Buyer, User, and Payer Segmentation

The Medicare Advantage market has a tripartite commercial structure: the beneficiary (user) selects the plan, CMS (payer) funds the capitation revenue, and the MAO (plan) bears the full actuarial risk. This structure creates a government-funded consumer market where beneficiary satisfaction and benefit design drive enrollment, but regulatory compliance and risk coding determine revenue adequacy. The primary buyer is a Medicare-eligible senior (age 65+) or disabled/ESRD beneficiary. The Annual Enrollment Period (AEP) runs October 15 through December 7 each year; a secondary Open Enrollment Period (OEP) from January 1 through March 31 allows enrolled MA members to switch once. Independent brokers, agents, and third-party marketing organizations (TPMOs) intermediated an estimated 60–70% of new MA sales before CMS introduced new TPMO compensation restrictions. HMO plans represent approximately 56% of non-SNP plan offerings, while PPOs represent roughly 44% of all MA plans. SNPs account for approximately 21% of total MA enrollment, with D-SNPs (dual-eligible) comprising 83% of SNP enrollment and C-SNPs the fastest-growing type. Four principal buyer archetypes dominate the segment map: (1) cost-sensitive 65+ seniors seeking $0-premium HMO plans with supplemental benefits; (2) geographically mobile seniors preferring PPO out-of-network flexibility; (3) dual-eligible low-income seniors served by D-SNPs, which coordinate Medicare and Medicaid benefits under state alignment contracts; and (4) seniors with qualifying chronic conditions—diabetes, CHF, COPD, cancer—served by C-SNPs that deliver condition-specific care management, clinical coordinators, and tailored supplemental benefit packages. The market is highly concentrated: UnitedHealthcare and Humana together control approximately 46–47% of national MA enrollment, and 97% of US counties are highly or very highly concentrated by HHI, leaving limited room for new entrants in most geographies outside of targeted expansion into underserved SNP populations. [CM013, CM014, CM015, CM016, CM017, CM018]

2.4 Growth Drivers and Adoption Constraints

Medicare Advantage growth is underpinned by the most durable demand driver in US healthcare: approximately 10,000 Americans turn 65 each day, adding roughly 1.5 million new Medicare-eligible beneficiaries annually. This demographic wave will continue for more than a decade. The program's bipartisan political durability—embedded in Medicare's infrastructure since the Medicare Modernization Act of 2003—and the CBO projection of 64% penetration by 2034 reinforce the structural demand thesis. Supplemental benefits are a powerful pull factor: average supplemental benefit value reached approximately $211 per member per month in 2025, up 76% from approximately $120 PMPM in 2021, as plans competed aggressively on benefit richness. Traditional FFS Medicare offers no equivalent coverage for dental, vision, hearing, or OTC needs. The C-SNP segment in particular combines demographic tailwinds (chronically ill seniors as the fastest-growing MA sub-population) with higher risk-adjusted revenue (complex chronic conditions generate higher HCC risk scores) and lower competitive intensity (D-SNPs require state contracting, I-SNPs require facility alignment, and C-SNPs require clinical infrastructure most incumbents lack). C-SNP enrollment grew approximately 49% in 2026; Devoted Health alone expanded its C-SNP footprint from 4 to 122 county-level plans in a single year. Constraints are material and near-term. The V28 risk model was fully phased in at 100% in CY2026, reducing countable ICD-10 codes from ~9,800 to ~7,700 and cutting plan revenue by approximately 3.01% directly. The OIG is running an active audit of coding intensity patterns; CMS anticipated more than $7.6 billion in annual savings from V28 in 2024 alone. Star ratings present a compounding headwind: only 64–67% of MA enrollees are in 4+ star plans in 2026 (versus ~80% historically), compressing quality bonus payments industry-wide—Humana saw only 20% of its members in qualifying plans. Six MAOs fully exited the market in 2026, forcing ~2.7 million non-SNP enrollees to re-shop. UnitedHealthcare shed plans covering 600,000+ members for 2026 on top of 900,000+ exits in 2025. Milliman estimated 2026 total value added declined more than 7% across the industry; Part D deductibles rose from ~$230 to ~$375. MedPAC's March 2026 analysis estimates MA costs CMS approximately $76 billion more per year than equivalent FFS care, sustaining regulatory pressure for payment reform throughout the forecast horizon. Broker compensation rule changes and pending TPMO litigation add channel distribution uncertainty. [CM020, CM021, CM022, CM023, CM024, CM025]

2.5 Exhibits

3.1 Competitive Landscape

The Medicare Advantage market serves approximately 35.4 million beneficiaries as of early 2026, representing 51% of all Medicare-eligible adults. The competitive structure is highly tiered: three national incumbents (UnitedHealthcare, Humana, CVS/Aetna) collectively serve roughly 20 million members and control a disproportionate share of local markets. KFF analysis of 2024 CMS enrollment data found that 97% of counties qualify as highly or very highly concentrated MA markets under Herfindahl-Hirschman Index criteria, and 90% of beneficiaries live in a county where one or two insurers enroll at least half of all MA enrollees. UnitedHealthcare dominates as the largest insurer in 41% of all counties, Humana in 25%. Enrollment growth has decelerated markedly. Annual MA enrollment growth was historically 7–10%, but fell to approximately 3% in 2026 as insurers retrenched in response to two consecutive years of reimbursement rate headwinds, rising medical utilization, and star-rating pressures. Several insurers—UHC, CVS/Aetna, Elevance, and Centene—shed tens to hundreds of thousands of MA members for the 2026 plan year, while Humana and Devoted Health grew. Milliman's analysis of 2024 financial filings reported the composite MA underwriting margin turned negative at -0.7%, down from +1.1% in 2023, affecting the full industry. The tech-enabled MA peer cohort—once including Oscar, Bright Health, Cano Health, Clover, and Alignment—has consolidated substantially. Oscar exited MA entirely in 2022–2023. Bright Health collapsed and exited its insurance business. Cano Health filed for Chapter 11 bankruptcy in February 2024. Clover and Alignment survived but experienced persistent net losses before turning to narrow profitability in 2024. Devoted Health, remaining private and VC-backed, more than doubled its membership during the 2025–26 AEP to approximately 470,000 members, positioning it as a survivor and a scale player among the tech-enabled cohort. The exits of failed peers created member displacement opportunities that benefited Devoted, Alignment, and Clover. Regional and nonprofit players—SCAN Health Plan, Kaiser Permanente, and VBC-specialist ChenMed—occupy differentiated niches less directly threatened by incumbent consolidation. Emerging CSNP-focused startups like Zing Health represent a growing adjacency in chronic-condition-focused special needs plans. [CP001, CP003, CP004, CP005, CP006, CP007]

3.2 Direct Competitors: Tech-Enabled MA Peers

Clover Health (Nasdaq: CLOV) is the most technically comparable public peer. Operating in NJ, PA, TN, TX, GA, and AZ, Clover offers primarily wide-network PPO plans powered by its proprietary Clover Assistant AI platform, which aggregates patient data to guide primary care physicians toward preventive interventions. Full-year 2024 insurance revenue was $1.34 billion with adjusted EBITDA of $70 million—its first year of positive EBITDA, reflecting an improvement of $112 million year-over-year. Net GAAP loss from continuing operations improved to $46 million in 2024 from $210 million in 2023. Clover grew 53% during the 2025–26 AEP to approximately 153,000 members and expects first-ever full-year GAAP net income profitability in 2026. A significant risk: Clover's largest contract, covering 97% of its members, dropped below the 4-star threshold for 2026, potentially eliminating quality bonus payments and costing tens of millions in EBITDA according to Leerink Partners analysts. Alignment Healthcare (Nasdaq: ALHC) is a California-headquartered tech-enabled MA plan with the AVA (Advanced Value-based Architecture) platform that integrates claims, clinical, and operational data. Full-year 2024 revenue was $2.70 billion (+48.3% YoY) with 189,100 members at year-end 2024, growing 58.6% YoY. The company achieved its first full year of positive adjusted EBITDA as a public company in 2024 ($1.3 million) and reported a net loss of $128.1 million. Alignment's 2026 AEP performance added members to reach ~280,000. Critically, Alignment achieved 100% of its members in plans with 4-star or higher ratings for 2026—a meaningful quality signal. For 2025 revenue guidance was $3.72–3.78 billion, representing 37–40% growth. Oscar Health fully exited Medicare Advantage by 2023, shifting focus to ACA individual and small-group markets where it had ~1 million members. CEO Mario Schlosser cited structural challenges executing MA in a scalable way without deep provider partnerships. Oscar's MA membership never exceeded several thousand members at peak, making it a minor competitive overlap. Bright Health exited its insurance business entirely in 2023 amid near-bankruptcy conditions, having overextended geographically across ACA and MA markets. The company sold its California MA assets (Brand New Day, Central Health Plan, ~125,000 members) and pivoted to its NeueHealth care delivery subsidiary. Bright Health's collapse demonstrated the catastrophic risk of rapid MA expansion without sufficient capital and risk management discipline. Cano Health, a value-based primary care provider to MA members, filed for Chapter 11 bankruptcy in February 2024 with over $1 billion in funded debt. It had been valued at $4.4 billion post-IPO in 2021. Cano emerged from bankruptcy in July 2024 as a private company, converting $1 billion of debt to equity and securing $200 million in fresh capital. The company is now focused on 80 Florida clinics. Cano's collapse underscores the sensitivity of capitated care models to risk adjustment changes and MA rate compression. [CP013, CP014, CP015, CP016, CP017, CP018]

3.3 Incumbent Players: Scale Payers

UnitedHealthcare (UHC), the MA market's largest insurer, enrolled approximately 9.4 million MA members as of February 2026—down 9% from 10.3 million before the AEP as the company aggressively exited plans serving over 600,000 members to recover margins. Despite the pullback, UHC retains commanding market position: it is the largest insurer in 41% of all US counties. UHC's 78% of members in 4-star+ plans for 2026 is strong and improved from 75% in 2025. Its parent UnitedHealth Group operates Optum, one of the largest health services and analytics platforms in the US, giving it unmatched data assets, care delivery integration via OptumCare, and pharmacy benefit management via OptumRx. However, UHC significantly underestimated accelerating medical cost trends for 2025, with executives citing "intensifying services costing more" across most encounters. Humana, the second-largest MA insurer, made an unusual contrarian bet for 2026, growing to over 7 million MA members from 5.8 million before AEP—adding roughly 1.2 million members while peers contracted. This growth gamble follows Humana's aggressive benefit reduction strategy in 2024–2025 that contracted its book to improve margins. Humana's 2026 star rating deteriorated, however: only 20% of members are in plans with 4-star+ ratings for 2026 (down from 25% in 2025), and average star rating for 2026 is 3.61. Humana has deep CenterWell senior-focused primary care infrastructure and a long VBC partnership with ChenMed, making it the most clinically integrated of the national incumbents. CVS Health / Aetna, the third-largest MA insurer with ~4 million members, integrated Oak Street Health (acquired for $10.6 billion in 2023) to build a differentiated primary care delivery asset. Oak Street operates roughly 200 primary care clinics across 25+ states focused on complex MA populations. Aetna led peers in the share of members in 4-star+ plans (81% for 2026, though down from 89% in 2025). CVS has been retrenching MA to optimize margins after heavy losses in 2024. Elevance Health (formerly Anthem) serves ~1.9 million MA members for 2026, down from 2.2 million, with 53% in 4-star+ plans—an improvement from 40% in 2025. Centene, the sixth-largest MA insurer, covers under 1 million members for 2026 after a 4% decline; its 4-star+ share improved dramatically from 1% to 18% for 2026. Both Elevance and Centene have Medicaid-heavy histories and are building MA presence through DSNP/CSNP expansion. [CP001, CP002, CP003, CP004, CP005, CP006]

3.4 Regional and Value-Based Care Peers

SCAN Health Plan is one of the nation's largest nonprofit MA plans, serving seniors across 33 California counties as well as markets in Arizona, Nevada, Texas, New Mexico, and Washington. Founded nearly five decades ago, SCAN emphasizes nonprofit mission and benefit stability. For 2026, SCAN announced expanded benefits including $0 copay for primary care and Tier 1/2 drugs, significant dental allowances ($800–$4,000), and enhanced vision coverage. In a contracting market, SCAN's CEO Dr. Sachin Jain positioned SCAN as "a stable and consistent partner for older adults" as for-profit plans retreated. SCAN's nonprofit status, deep California roots, and mission alignment with senior care differentiate it from for-profit peers, though its geographic reach remains concentrated in California relative to national incumbents. ChenMed is a privately held capitated primary care company operating 120+ senior medical centers in 15 states under the Chen Senior Medical Center, Dedicated Senior Medical Center, and JenCare brands. ChenMed is not an MA insurer but operates as a downstream VBC partner: it accepts full-risk capitation from MA payers, bears medical cost risk, and shares savings from better outcomes. ChenMed has a long-standing partnership with Humana, formalized through a new five-year network agreement in February 2023, ensuring in-network access for Humana MA members at all ChenMed locations. ChenMed's concierge-style, physician-led model for complex low-income Medicare seniors is viewed as one of the highest-performing primary care platforms in the country. As a provider/capitation partner rather than a competing payer, ChenMed is both a potential partner and a model benchmark for Devoted Medical. Zing Health, founded in 2019 out of the American Medical Association's Health 2047 innovation lab by Dr. Eric Whitaker and Garfield Collins, focuses on Chronic Special Needs Plans (CSNPs) for underserved seniors with chronic conditions. Zing raised $140 million in September 2024, with participation from Health 2047 Capital Partners, CRG, and First Trust Capital Partners. Zing has been one of the fastest growing MA plans since 2023, with most members selecting CSNPs. It competes primarily in markets where traditional MA plans are not designed to handle chronic, complex populations. Zing's CSNP focus and community-based model represent a growing segment of the MA market, as CMS data shows CSNP enrollment grew 49% for 2026 according to Healthscape's analysis. Kaiser Permanente's integrated model—owned hospitals, employed physicians, and its own MA plans—covers approximately 2 million MA members for 2026. Virtually all Kaiser MA members remain in plans with 4-star+ ratings. Kaiser's geographic concentration in California, Pacific Northwest, Colorado, and Mid-Atlantic regions limits direct overlap with Devoted Health's footprint but demonstrates the viable ceiling of integrated care models at scale. [CP027, CP028, CP029, CP030, CP031, CP032]

3.5 Switching Costs, Moats, and Competitive Dynamics

Medicare Advantage beneficiaries face moderate structural switching costs. Annual enrollment periods (Oct 15–Dec 7) create natural friction: members must actively re-enroll to switch plans, and changing plans may disrupt provider relationships if networks differ. Studies show high MA member retention rates industry-wide, with Clover reporting over 95% AEP member retention for 2026, suggesting that once enrolled, members rarely switch without a compelling reason (benefit cuts, plan exit, physician changes). However, the 2025–26 AEP saw atypical turbulence as millions of seniors were displaced by UHC, Aetna, and other insurer plan exits—creating an unusual window for growth for plans like Devoted Health and Alignment. Star ratings function as a self-reinforcing moat for high-performing plans. Plans with 4-star+ ratings receive quality bonus payments from CMS and can submit lower bids (since they receive higher rebates), enabling richer supplemental benefits that attract and retain members. Devoted Health's 95% of members in 4-star+ contracts for 2026 gives it a compounding revenue advantage over lower-rated competitors. Clover's drop below 4-stars for its largest contract in 2026 illustrates the asymmetric downside of star rating declines—analysts estimated it could wipe out Clover's entire EBITDA. Distribution power is a significant incumbent moat. UHC, Humana, and Aetna maintain extensive broker networks, brand recognition, and marketing budgets that far exceed smaller plans. Independent agents and brokers drive a significant share of MA enrollment decisions, and incumbents' established relationships limit smaller plans' cost-efficient access to new members. Devoted Health's use of direct-to-consumer marketing, member guides, and word-of-mouth through its care model is differentiated but faces scaling challenges against incumbents' broker infrastructure. Provider access and network adequacy present both moats and challenges. Incumbents' scale enables favorable contracting with hospitals and specialist groups. Devoted's Devoted Medical model—integrated in-house virtual and in-home primary care—partially sidesteps this by owning clinical relationships, but also requires ongoing investment in clinical staff and technology. ChenMed's capitation model shows that deep physician alignment can produce superior outcomes for complex populations, and Devoted's model echoes this philosophy but within a payer-controlled structure rather than a standalone medical group. The risk of commoditization is real: as technology becomes more accessible, differentiated clinical capabilities that today require proprietary platforms may become table stakes, potentially compressing margins across the sector. [CP014, CP025, CP033, CP034, CP040]

3.6 Exhibits

4.1 Revenue Model and Pricing

Devoted Health operates as a Medicare Advantage (MA) insurer; its primary revenue source is monthly capitation payments from the Centers for Medicare & Medicaid Services (CMS). CMS pays MA plans based on risk-adjusted county benchmark rates, with per-member-per-month (PMPM) amounts calibrated to each member's expected health costs using the Hierarchical Condition Category (HCC) risk-adjustment model. Devoted bids below the county benchmark to qualify for CMS rebates, which it uses to fund $0-premium plans with supplemental benefits—eliminating member premiums as a significant revenue source while building enrollment scale. The company also earns quality bonus payments from CMS for plans rated 4 stars or higher; Devoted's average Star Rating reached 4.6, with 95% of 2026 members in 4-star-or-better contracts, qualifying for the 5% quality bonus on capitation payments. Revenue grew from approximately $1.93 billion in 2023 to $3.27 billion in 2024, a 69% increase, reflecting a 71% membership increase to 244,763 members at year-end. Average annual revenue per member in 2024 was approximately $13,400 (~$1,117 per member per month), derived from CMS capitation. Revenue recognition follows standard insurance premium-earned accounting. Consolidated revenue and the full P&L including corporate parent and Devoted Medical costs are not publicly disclosed; the $3.27 billion figure represents regulated health plan entities only as disclosed in state insurance regulatory filings. Membership reached approximately 466,000 as of January 2026 as Devoted expanded to 29 states, implying annualized 2026 revenue in the range of $5–6.5 billion if ARPM is maintained.[CI001, CI002, CI003, CI004, CI005, CI024]

4.2 Unit Economics and MLR Benchmarks

The Medical Loss Ratio (MLR)—medical claims paid divided by premium revenue—is the primary unit economics indicator for MA insurers, and the CMS minimum is 85%. Devoted's MLR has improved materially: 94% in 2022, 89% in 2023, and approximately 86% in 2024, converging toward the sustainable zone for MA plans. For comparison, Alignment Healthcare reported an 88.8% medical benefits ratio for full-year 2024. Devoted's 2023 regulated-plan operating loss widened to $55.4 million (from $35.3 million in 2022), but by Q1 2024 the health plan entities reported positive net income of $11 million versus a $8.9 million loss in Q1 2023, reflecting the MLR improvement and operating leverage from scale. Shelby Livingston's April 2025 analysis of 33 state insurance filings for 2024 reported total revenue of approximately $3.3 billion and shrinking operating losses, with health plans net-positive on a combined basis when investment income is included. The V28 CMS-HCC risk model transition (phased 2024–2026) reduced the number of eligible ICD-10 diagnosis codes from approximately 9,800 to 7,700, cutting risk-score RAF values and reducing MA revenues by approximately 3.12% per year. This headwind is likely embedded in the 2024 results; the V28 impact is expected to be fully absorbed by 2026. Devoted responded to cost pressures by cutting approximately 5% of its workforce in May 2025. Key unit economics including CAC, contribution margin by market, and the Devoted Medical operating subsidy remain private and unquantifiable from public data.[CI005, CI006, CI007, CI008, CI009, CI010]

4.3 Capital Stack and Financing History

Devoted Health has raised approximately $2.64–2.7 billion in equity capital across nine disclosed rounds since its 2017 founding. The Series B ($300M, 2018) and Series C ($450M, 2020) provided early operating capital. The defining round was the Series D ($1.15 billion, October 2021), co-led by Uprising and SoftBank Vision Fund 2, with participation from GIC, Andreessen Horowitz, ICONIQ Growth, General Catalyst, and Emerson Collective, at a post-money valuation of $12.6–12.7 billion. Latham & Watkins LLP's announcement confirms SoftBank Vision Fund 2 as the largest single Series D investor. A Series E of $175 million closed December 29, 2023, led by a syndicate including The Space Between, Highbury Holdings, GIC, Stardust Equity, Maverick Ventures, and Fearless Ventures, with participation from Andreessen Horowitz and General Catalyst. Prime Unicorn Index analysis of SEC filings shows the Series E was priced at $56.25 per share—the same price as the Series D—indicating essentially flat per-share valuation rather than a markdown. A $112 million Series E extension closed in August 2024 at a reported $13 billion post-money valuation. Most recently, Devoted raised $48 million in a Series F (November 2025) and $317 million in a Series F-Prime (January 2026) led by The Space Between and Centricus, with new investors GV, VZ Ventures, and Morgan Health. Total cumulative capital raised is approximately $2.64 billion per Sacra's analysis. Cash on hand, monthly burn rate, and runway are not publicly disclosed and represent a material diligence gap; the May 2025 workforce reduction of 5% suggests active cost management potentially driven by burn rate discipline.[CI016, CI017, CI018, CI019, CI020, CI021]

4.4 Financial Gaps and Diligence Blockers

Devoted Health is a private company with no obligation to publish consolidated financial statements. All publicly available financial data derive from state insurance regulatory filings, which cover only the regulated health plan subsidiaries—not the corporate parent, the Devoted Medical medical group, or the Orinoco technology platform entity. This creates a systematic gap: state filings exclude corporate overhead, technology capitalization or expense, broker and marketing costs, and the intercompany economics between the insurance plans and Devoted Medical. The Orinoco platform is described as a full-stack payer and provider operations platform, suggesting significant ongoing technology investment that is excluded from plan-level filings. CMS requires MA plans to maintain at least an 85% MLR, with member rebates owed if exceeded; this creates a structural ceiling on plan-level margin, making cost discipline and volume scale the primary levers to profitability. The biggest diligence blockers for a financial assessment are: (1) consolidated cash and burn rate unknown; (2) CAC and marketing spend unknown; (3) gross margin by geography and product line unknown; (4) whether Devoted Medical is profitable or subsidized by the insurance plans is unknown; and (5) the treatment of Orinoco capitalization versus expensing is unknown. Secondary risks include CMS's 2026 payment rate environment and ongoing V28 risk model headwinds. The company's most recent 2026 funding tranches suggest capital access remains viable, but the absence of a profitability timeline disclosure is a persistent concern for return of capital analysis.[CI034, CI035, CI036, CI037, CI038, CI040]

5.1 MA Plans, Plan Types & Member Workflow

Devoted Health offers Medicare Advantage plans in four structures: HMO, PPO, Dual Eligible Special Needs Plan (D-SNP), and Chronic Condition Special Needs Plan (C-SNP). Plans are available across 29 states as of 2026, expanded from 20 states in 2024. All plans replace traditional Medicare Parts A, B, and D with an integrated card; supplemental benefits on select plans include dental, vision, hearing, a Food and Home Card (managed by Optum Financial's Healthy Benefits+ platform), SilverSneakers fitness access, transportation, and meal delivery. Each enrolled member is assigned a Devoted Guide — a care navigator reachable by phone or text from 8 am to 8 pm weekdays — who coordinates benefits, schedules appointments, resolves billing issues, and connects members with community resources. Devoted Medical augments the plan with 24/7 virtual Care On Demand and in-home primary care at no copay. CMS awarded Devoted a 2025 weighted average of 4.3 Stars across 15 rated contracts, with 88% of rated-plan members in 4-star-or-higher plans. For 2026, 95% of all members are enrolled in 4-Star-or-better contracts, reflecting the platform's care quality delivery.[CE001, CE002, CE012, CE013, CE014, CE015]

5.2 Orinoco Platform & Technical Architecture

Orinoco is Devoted Health's proprietary platform-as-a-service (PaaS), publicly described as "the first modern software platform that can support the entirety of payor and healthcare provider operations, end to end, in a highly integrated way." Its capabilities span healthcare operations data management, CRM, task-based care management, and healthcare service coordination — all delivered through a secure, web-based interface with no client-side installations required. The platform ingests claims data and electronic health records, runs care-gap identification, assigns tasks to Guides and clinicians in real time, and generates quality-measure reporting for CMS Star Ratings compliance. Confirmed by public job postings on Venrock, Devoted's engineering stack comprises Go (primary backend language), PostgreSQL (relational database), gRPC and GraphQL (API layers), React and TypeScript (frontend), Terraform (infrastructure as code), and AWS (cloud hosting). The DevotedHealth GitHub organization (26 public repositories) demonstrates this stack: the most popular repo is terraform-provider-looker (Go, 3 stars, 24 forks), confirming Looker use for BI; in-memory-db-starter (TypeScript) is the engineering hiring assessment template; Pyrseas (Python) is a PostgreSQL schema migration fork. Co-founder Ed Park credited Devoted's build-everything-simultaneously approach — not a sequential layer build — for enabling rapid Star Rating achievement by ensuring insurance, clinical, service, and data functions share a single source of truth.[CE003, CE004, CE005, CE006, CE007, CE008]

5.3 Devoted Medical & Clinical Technology

Devoted Medical is the in-house virtual-first and in-home medical group built specifically for the Medicare population. It delivers 24/7 Care On Demand (telehealth), annual comprehensive health assessments, medication delivery, and in-home follow-up visits where available — all at no copay to members. Over 90% of Devoted Medical's encounters are delivered telemedically, a shift accelerated during COVID-19 when Devoted built a custom video conferencing module optimized for seniors. For members lacking their own devices, Devoted shipped cellular-equipped iPads; the company also provided pulse oximeters, wireless scales, and wireless blood pressure cuffs whose readings integrate into the Orinoco clinical workflow for continuous monitoring and proactive outreach. Devoted Medical's EHR was built from scratch. Clinicians are instructed to "not remember anything — emote, connect, feel, and software will remember everything for you," with Orinoco surfacing all relevant prompts and care-gap tasks autonomously. The average Devoted Medical clinician has eight years of experience. DevotedDoc, a spin-out, extends this telehealth infrastructure to correctional systems and safety-net providers, offering virtual addiction-specialty care and other services as a B2B product, representing early monetization of the clinical platform beyond the core Medicare Advantage membership.[CE013, CE016, CE017, CE018, CE019, CE020]

5.4 Digital Member Tools & Integration Partners

The MyDevoted app (iOS: App Store ID 6748701214; Android: com.devotedhealth.memberportal) provides enrolled members with mobile access to their member ID card, referral and authorization tracking, Devoted Medical visit scheduling, drug formulary lookup, premium and claim reimbursement payments, Health Risk Assessment completion, plan document access, and Food and Home Card management. The my.devoted.com web portal offers equivalent functionality for members who prefer a browser-based experience. Integration partners include Optum Financial (Healthy Benefits+ card for OTC/food eligible members with chronic conditions), SilverSneakers by Tivity Health (fitness), and the Devoted agent portal (broker certification and enrollment). As of January 1, 2026, Magellan Healthcare no longer manages behavioral health services for Devoted members; Devoted now processes behavioral health authorizations and claims in-house, which will require corresponding Orinoco workflow capability. Provider network tooling, quick reference guides, and prior-authorization resources are hosted at devoted.com/providers/ for in-network physicians.[CE024, CE025, CE032, CE033, CE034, CE035]

5.5 Compliance, Security & Product Risks

Devoted Health operates under CMS Medicare Advantage contracts and maintains a Medicare Compliance Program covering fraud, waste, and abuse (FWA) prevention, HIPAA, OIG/GSA exclusion screening, Anti-Bribery/Anti-Corruption, and Conflict of Interest policies. An anonymous FWA hotline (855-292-7485) and compliance@devoted.com are active reporting channels, and Devoted enforces a zero-tolerance retaliation policy. For HIPAA, Devoted publishes a dedicated policy; HIPAA compliance is a legal prerequisite for CMS contracting. However, no public HITRUST or SOC2 certification has been announced — a material gap for a platform processing protected health information for 466,000+ members on shared AWS cloud infrastructure. No public uptime SLA, disaster recovery documentation, or API security specification has been disclosed. The May 2025 layoff of approximately 120 employees (~5% of 2,460 staff) affected all departments and could slow Orinoco feature velocity. CMS V28 risk-model implementation and 2026 rate structure changes create ongoing financial pressure that could constrain the technology investment budget. Devoted Medical's telehealth-first care model introduces clinical risk for members in acute distress if connectivity is interrupted or response time is delayed before emergency escalation.[CE037, CE038, CE039, CE041, CE042, CE043]

5.6 Exhibits

6.1 Member Demographics and Customer Segments

Devoted Health's customers are Medicare-eligible seniors aged 65 and older enrolled in its Medicare Advantage (MA) HMO and PPO plans. Unlike enterprise SaaS companies, Devoted operates as a B2C insurer: the buyer, user, and payer are the same individual — a senior beneficiary who selects Devoted through the CMS annual enrollment period (AEP), a Medicare broker, or directly via devoted.com. As of January 2026, Devoted serves over 466,000 members across 29 states, with the largest member concentrations historically in Florida, Texas, and Ohio. The company offers both standard Medicare Advantage HMO and PPO products and Dual-Eligible Special Needs Plans (D-SNPs) for beneficiaries who qualify for both Medicare and Medicaid. For 2026, D-SNP plans are available in 14 states including Florida, Texas, Ohio, North Carolina, Colorado, and Alabama. Chronic Condition SNPs (C-SNPs) are offered in select markets. Approximately 92% of Devoted's plans carry a $0 monthly premium, positioning the company in the affordability segment of the MA market. The population skews toward seniors with multiple chronic conditions — hypertension, diabetes, and cardiovascular disease — consistent with the MA market broadly. Devoted Medical, the integrated virtual-first and in-home clinical group, provides care to the member base and is central to Devoted's differentiated retention model.[CU001, CU003, CU008, CU018, CU031, CU034]

6.2 Enrollment Scale and Adoption Trajectory

Devoted grew from roughly 82,000 members at end-2022 to 466,000 as of January 2026, a compound annual growth rate far outpacing the market. For plan year 2026, Devoted reported a 121% year-over-year membership increase — the highest percentage growth rate among MA parent organizations with over 100,000 members. This expansion was driven by the 2025 AEP (October–December 2025), during which Devoted entered nine additional states to reach 29 total. In 2024, the company served 244,763 members and recorded health-plan revenue of $3.3 billion (+69% YoY). In 2023, membership stood at approximately 143,000 and revenue was $1.9 billion (+76% YoY). State filings for Q1 2024 showed enrollment reaching approximately 212,000 by March 31. Devoted describes itself as the fastest-growing and eighth-largest MA carrier as of early 2026. Nationally, MA market enrollment grew only 0.3% during AEP 2026 — well below Devoted's surge — indicating market share capture rather than market-wide expansion. The top states for AEP 2026 overall MA growth were Texas (+35k), Florida (+27k), and North Carolina (+23k), all core Devoted geographies. Devoted's C-SNP applications ranked among the top three carriers during AEP 2026. The company also closed $366 million in Series F and F-Prime equity funding in November 2025 and January 2026 to fuel continued expansion.[CU001, CU002, CU003, CU005, CU006, CU007]

6.3 CMS Star Ratings, Member Satisfaction, and Named Proof

Devoted's member quality is validated externally through CMS Medicare Advantage Star Ratings, which measure clinical outcomes, member experience, and customer service. For 2026, three Devoted contracts earned 5 out of 5 stars: Devoted Health Plan of Florida (H1290), Devoted Health Plan of North Carolina (H5299), and Devoted Health Plan of Texas (H7993). Of 18 total five-star contracts industry-wide, Devoted holds three. For 2025, Devoted achieved a weighted average of 4.3 stars across 15 rated contracts versus the national average of 3.9. One hundred percent of 2024-rated contracts retained 4+ stars for 2025, and 50% of newly rated first-year contracts earned 4+ stars (vs. a historical 12% rate). For 2026, 100% of Devoted members in Star-eligible plans are enrolled in plans rated 4+ stars on Statin Therapy and Medication Reconciliation. Ninety-six percent of members are in 4+ star plans for Controlling Blood Pressure, 98% for the Health Plan Rating, and 95% for Customer Service. US News rated Devoted Health 4 out of 5 overall and 4.2 on screening and prevention, versus 3.7 for UnitedHealthcare on the same dimension. Member satisfaction surveys show 95% of members have recommended or would recommend Devoted to family or friends, and 93% trust that Devoted keeps its promise to get them needed care. As of 2021, Devoted reported an NPS of 79, which it described as higher than Apple, Netflix, and Amazon at that time.[CU004, CU013, CU014, CU015, CU024, CU025]

6.4 Retention, Durability, and Adverse Evidence

Devoted lacks publicly disclosed cohort-level disenrollment data; however, proxy signals indicate above-average retention. Member voluntary disenrollment is one of CMS's graded metrics embedded in Star Ratings; Devoted's multi-plan 4.5-star performance for 2025 implies disenrollment rates in the top quartile of the industry. The broader MA market experiences annual voluntary disenrollment of roughly 8–15%; high-performing plans typically retain 88–92% of members annually. BBB records 47 total complaints against Devoted Health over the three years ending mid-2026, with 20 closed in the last 12 months. Devoted is not BBB Accredited. Complaint categories include service-or-repair issues (30), product issues (5), order issues (4), and billing issues (3). Member reviews on the BBB platform document specific failure modes: OTC benefit items consistently out of stock or missing from orders; medical transportation delays; provider directory inaccuracies listing out-of-network physicians as in-network; and lengthy wait times for specialty referrals. These are consistent with the operational complexity of scaling a vertically integrated MA plan into new geographies. US News scores Devoted 2.8 out of 5 on customer satisfaction, below its 4.2 on screening and prevention, suggesting that clinical performance outpaces service execution as the company scales. Devoted laid off 120 employees (5% of 2,460) in May 2025, which may reflect margin management ahead of profitability but has not been linked to service deterioration.[CU016, CU017, CU022, CU029, CU032, CU033]

6.5 Broker Channel, Expansion, and Concentration Risk

Devoted distributes almost entirely through the independent broker/agent channel. Brokers use a dedicated Agent Portal to submit enrollments, run Medicare/Medicaid eligibility checks, access plan documents, and manage commission statements. For 2026 AEP marketing, Devoted provided a comprehensive storefront with plan-at-a-glance guides and enrollment materials across all states. In Devoted's own broker surveys (2025), 96% of brokers rated its agent support better than that of other MA carriers, and 95% said Devoted listens to and acts on broker feedback. During AEP 2026, Devoted's C-SNP applications ranked among the top three carriers alongside Humana and UnitedHealthcare on the Spark Advisors platform. Geographic expansion risk is material: nine states were added in a single AEP cycle for plan year 2026, and operational quality must scale simultaneously. Member concentration is inherently diversified by the nature of an individual- beneficiary insurance model — no single member represents a meaningful revenue share. Provider partnership risk exists, however: Devoted's HMO plans depend on network adequacy in each county, and if key health-system partners reduce MA contracting (as has occurred with Humana and Kettering Health), access disruption can trigger disenrollments. B2C concentration by geography is notable: Florida and Texas remain the largest states by member volume, and any deterioration in star ratings or network adequacy in those states would disproportionately affect Devoted's overall performance.[CU001, CU009, CU010, CU011, CU034, CU039]

6.6 Exhibits

7.1 Regulatory and Reimbursement Risks

Devoted Health's economics are entirely governed by CMS rate-setting and regulatory compliance. The most immediate structural threat is the full phase-in of the CMS-HCC Version 28 (V28) risk-adjustment model in 2026, which now computes 100% of MA risk scores under the new framework. V28 removed or merged approximately 2,000 ICD-10 codes, reclassified chronic conditions, and recalibrated demographic coefficients; industry analyses estimate this reduces average RAF scores by 5–8%, with CMS itself projecting a 3.12% average decline during the initial 2024 rollout. The OIG has announced a formal audit (announced January 2026, estimated completion FY2028) to verify whether CMS achieved its projected $7.6B savings target from V28 for payment year 2024—creating additional retroactive compliance scrutiny for all MA plans. On the rate side, CMS finalized a 5.06% average increase in 2026 MA payments—a positive development after 2025 cuts—but the increase is unevenly distributed and does not fully compensate for V28-driven RAF compression or rising utilization. The 2025 CMS Final Rule's broker compensation provisions were vacated by a Texas federal court in August 2025 (ruling CMS lacked statutory authority for rate-making), while the MA audit program expanded in May 2025 to cover all eligible contracts for payment years 2018–2024, introducing retroactive payment-accuracy risk. MA star-rating litigation—Elevance lost its challenge to CMS's 2024 star-rating methodology (forfeiting an estimated $375M in bonus payments) and Humana's parallel suit was dismissed— signals that MA plans face both financial exposure from lower star ratings and limited legal recourse. Devoted's competitive advantage is partly anchored to its star ratings; losing 4+ star status on any significant contracts would reduce bonus payments and potentially trigger benefit cuts affecting retention.[CR001, CR002, CR003, CR004, CR005, CR006]

7.2 Financial and Capital Risks

Devoted Health has never reported a consolidated profit. State-filed health plan data for 2023 showed a $55.4M operating loss (up from $35.3M in 2022) and a net loss of $33.7M (approximately -1.75% margin) on $1.9B in plan revenues. The MLR was ~89% in 2023, above the 85% industry target. While Q1 2024 showed $11M net income at the plan level—its first positive quarterly result—the structural break-even path remains unclear, and Sacra's 2024 revenue estimate of $3.27B suggests the company is scaling into its losses rapidly in tandem with enrollment growth. Sector-wide, medical loss ratios continued worsening through Q3 2025 as insurers failed to anticipate the scale and speed of rising utilization, especially in MA. UnitedHealth, Humana, CVS, and Elevance all announced further MA market retractions for 2026, validating that even large-scale incumbents struggle with MA economics. For a growth-stage insurer like Devoted, the risk is that medical cost trends outpace premium growth and the company burns through its recently raised capital before reaching profitability. Devoted's $366M Series F (announced January 2026; two tranches: $48M in November 2025 and $317M in January 2026) extends runway and signals investor confidence, but the participation of 14+ investors highlights concentration risk if even a subset withdraws support for future rounds. Capital markets for healthcare growth-equity have been volatile, and Devoted's path to an exit (IPO or M&A) is uncertain given the premium-to-book valuations under pressure across the MA peer group.[CR011, CR012, CR013, CR014, CR015, CR016]

7.3 Competitive, Operational and Cyber Risks

Devoted Health competes in a structurally oligopolistic market. KFF's July 2025 analysis found that 79% of US counties were highly concentrated MA markets and 18% were very highly concentrated in 2024; United Healthcare held the top MA enrollment share in 41% of counties and Humana in 25%. UnitedHealthcare and Humana together comprised nearly 47% of national MA enrollment. Devoted, with roughly 466,000 members as of January 2026, remains a fraction of the scale of either incumbent, limiting its ability to negotiate provider contracts, absorb cost shocks, or invest in network density at equivalent unit economics. Sector failures—Bright Health's full exit, Cano Health's bankruptcy in February 2024, and Oscar Health's MA exit—demonstrate the lethal consequences of miscalibrated growth and market selection. Devoted's combination of rapid expansion into 29 states and a premium-positioned integrated care model is a differentiated strategy but amplifies execution risk if MLR targets slip. The Change Healthcare cyberattack in late February 2024 (a UnitedHealth subsidiary) disrupted claims processing, pharmacy operations, and prior authorization across the entire MA sector. CMS issued a directive on March 6, 2024 instructing all MA organizations to relax prior authorization requirements and offer provider advance funding. Devoted's dependency on third-party claims clearinghouses and vendor infrastructure—similar to every MA plan—means a comparable cyber incident could disrupt care delivery, trigger regulatory scrutiny, and create member experience damage. CMS's expanded audit program (2025) adds compliance-ops burden: MA organizations must demonstrate accurate diagnosis-code submission across multiple payment years, requiring ongoing investment in documentation, coding, and audit-response infrastructure.[CR021, CR022, CR023, CR024, CR025, CR026]

7.4 People, Execution and Mitigation Framework

Devoted Health's founders, Ed Park (CEO and Co-Founder) and Todd Park (Co-Founder and Executive Chairman), are the company's most visible risk and most important asset simultaneously. Ed Park was COO/CTO of Athenahealth; Todd Park was the first US Chief Technology Officer under President Obama and co-founded Castlight Health and Athenahealth. Their reputations and networks underpin investor confidence, provider relationships, and regulatory credibility. The departure of either—due to health, lifestyle change, regulatory friction, or competitive opportunity—could materially impair the company's ability to raise capital, attract talent, or maintain strategic direction. In May 2025, Devoted cut approximately 5% of its workforce, a small but notable signal of financial discipline in a period of persistent losses. The company has never disclosed a consolidated profitability timeline. Mitigating factors include Devoted's strong clinical performance: 100% of its members in star-eligible plans are in 4+ star plans on key clinical measures, three contracts earned CMS 5-Stars for 2026 (H1290, H5299, H7993), and the Series F investor syndicate includes strategic backers such as Morgan Health (JPMorganChase), GV (Google Ventures), and Franklin Templeton. Thesis-break triggers include: any CMS audit finding resulting in payment clawbacks exceeding $50M; star rating decline to below 3.5 stars on more than 20% of membership-weighted contracts; MLR deteriorating above 92% for two consecutive quarters; or a leadership departure (Ed or Todd Park) without a named successor.[CR031, CR032, CR033, CR034, CR035, CR036]

7.5 Exhibits

8.1 Investment Thesis and Recommendation

Devoted Health occupies a structurally attractive niche — vertically integrated Medicare Advantage with owned clinical services, a proprietary technology stack (Orinoco), and a genuinely differentiated member experience. Revenue has grown from ~$1.1 billion in 2022 to an estimated $3.3 billion in 2024, membership has expanded from ~140,000 in Dec 2023 to 466,000 by January 2026, and regulated health plan entities briefly achieved a small net income of $11 million in Q1 2024. The company has raised ~$2.64 billion total since founding, backed by SoftBank Vision Fund 2, Andreessen Horowitz, General Catalyst, GIC, and others. These facts support a genuine growth thesis. The anti-thesis is anchored in valuation discipline. At the last confirmed private valuation of ~$12.9–13.1 billion, Devoted trades at approximately 4x EV/Revenue on 2024 estimated revenues — versus 1.1–1.2x for comparable public Medicare Advantage insurers (ALHC, CLOV). The Series E round (Dec 2023) was priced at $56.25/share, the same per-share price as the Series D (Oct 2021), effectively a flat round that reflects investor caution even as revenue more than doubled. The company has not disclosed profitability at the consolidated level, and STAT News analysis of state regulatory filings confirms Devoted had not turned a profit through 2023. The Medicare Advantage sector faces structural headwinds — V28 risk model transition, CMS rate cuts, star-rating clawbacks — that compress sector multiples industry-wide. On balance, the recommendation is "track": the growth trajectory and clinical model are compelling, but entry at the current implied valuation (~$15 billion) requires a premium that is difficult to justify with publicly available evidence. Investors should monitor Q2 2026 state regulatory filings, the CMS 2027 rate announcement impact, and the company's path to consolidated profitability before committing capital. [CV001, CV002, CV003, CV004, CV005, CV006]

8.2 Financing History and N-PORT Fair Value Evidence

Devoted Health's funding history spans nine rounds from 2017 through January 2026, with the capital structure defined by five key data points. The Series B (Oct 2018, $300M) was priced at a ~$1.8 billion post-money valuation. The Series C (Apr 2020, $450M) valued the company at $3.78 billion. The Series D (Oct 2021, $1.15B) marked the valuation peak at $12.6 billion, with a further $80M add-on bringing the total to $1.23B Series D proceeds and a $12.7 billion final post-money. The Series E (Dec 2023, $175M) was confirmed at $12.87–13.1 billion by multiple sources close to the deal — effectively flat on a per-share basis ($56.25/share, same as Series D), confirmed by a Prime Unicorn Index analysis of the underlying Form D authorization. An August 2024 Series E extension of $112M was separately confirmed at approximately $13 billion by Sacra. Total raised stands at approximately $2.64 billion as of January 2026. The most granular mark-to-market evidence comes from SEC N-PORT filings by Private Shares Fund (CIK 0001557265, PIIVX), a named investor in the Series E and subsequent rounds. The fund discloses Devoted Health common share fair value quarterly. The series shows: $55.08/share (Sep 30, 2023), $56.25/share (Mar 31 and Sep 30, 2024), $64.64/share (Dec 31, 2024 — a 15% step-up from the Sep 2024 mark, consistent with the Aug 2024 Series E extension), $57.50/share (Sep 30, 2025 — a slight retreat ahead of the Series F), and $67.50/share (Dec 31, 2025 — a 17% step-up after the Series F closed in November 2025). The Dec 2025 mark of $67.50/share represents a 20% premium over the Series D/E issuance price of $56.25/share. Applying the same ratio to the confirmed Series E valuation ($12.87B) yields an implied enterprise value of approximately $15.4 billion as of December 2025, consistent with independent estimates (~$15B, Eboona, Feb 2026). No formal per-share price or enterprise valuation was disclosed for the Series F (~$366M total). Secondary market signals from Forge Global show the Devoted Health stock profile is active but all bid/ask data is obscured, providing no public secondary market price signal as of May 2026. [CV012, CV013, CV014, CV015, CV016, CV017]

8.3 Comparable Company Analysis

The most directly comparable public companies are Medicare Advantage insurtech peers: Alignment Healthcare (ALHC) and Clover Health (CLOV). Larger pure-play MA insurers such as Humana (HUM) provide a sector floor, though their scale and diversification make direct comparison imprecise. Oscar Health (OSCR) is included as a former MA insurer that has since exited the segment; its current ACA-focused multiple is directionally informative about the broader managed-care valuation environment. As of May 15–16, 2026: ALHC has an enterprise value of $3.05 billion on 2024 revenues of $2.70 billion (EV/Revenue: 1.13x), 189,100 Medicare Advantage members at Dec 31, 2024, and an EV/member of approximately $16,130. CLOV has an enterprise value of $1.66 billion on 2024 insurance revenues of $1.34 billion (EV/Revenue: 1.24x), approximately 80,000 average MA members in 2024, and an EV/member of approximately $20,750. Humana has an enterprise value of $45.60 billion at an EV/Revenue of 0.33x (full company, including CenterWell segment; MA-specific metrics are not isolated in this analysis). Oscar has an EV of $2.65 billion on 2024 revenues of $9.18 billion (EV/Revenue: 0.29x), though Oscar exited Medicare Advantage in 2023 and its current multiple reflects an ACA-focused business. Applying public comp EV/Revenue multiples to Devoted Health's estimated 2024 revenue of $3.27 billion yields an implied enterprise value of $3.7–4.1 billion (at ALHC/CLOV multiples). This is 3–3.5x below the last confirmed private round valuation of ~$13 billion. The premium is partially explained by Devoted's higher growth rate (69% YoY revenue growth in 2024 vs 48–59% for ALHC/CLOV), integrated clinical model, and proprietary technology platform. However, private-to-public comp discounts of this magnitude are historically difficult to justify without a near-term liquidity event or clear profitability trajectory. Per-member EV for Devoted at the last private round ($13B / 244,763 Dec 2024 members) is approximately $53,100 — roughly 2.6–3.3x the ALHC/CLOV per-member range of $16,000–$21,000. If valued at ALHC per-member multiples on 466,000 Jan 2026 members: 466,000 × $16,130 = ~$7.5 billion implied — still well below the private round level. [CV024, CV025, CV026, CV027, CV028, CV029]

8.4 Scenario Analysis and Exit Readiness

Three scenarios bound the investment decision. In the bear case, Medicare Advantage sector headwinds accelerate — CMS implements further rate cuts for 2027, the V28 risk model erodes Devoted's risk-adjusted revenue, consolidated losses widen, and growth slows below 20% as competitor exit creates enrollment disruption. A valuation of $4–6 billion is plausible at 1.2–1.8x 2024E revenue, representing a 55–69% decline from the ~$13 billion private round. In the base case, Devoted sustains 30–40% membership growth through 2026–2027, MLR stabilizes at 85–87%, and the company approaches consolidated breakeven. A Series G or strategic transaction at $12–16 billion (3.5–5x forward 2025E revenue of ~$4B) represents a plausible outcome consistent with the Series F implied mark. In the bull case, Devoted achieves 50%+ membership growth, launches profitable adjacencies (CenterWell-equivalent), and accesses the public markets via IPO at 4–6x forward revenue on ~$5B 2026E revenue, implying a $20–30 billion range. Exit pathways include: (1) IPO — market conditions for MA insurtech IPOs are challenging given sector multiple compression (ALHC at 0.8x forward PS, CLOV at 0.6x forward PS); (2) strategic acquisition by a major insurer (UnitedHealth, CVS/Aetna, Humana) or tech-enabled care company — the $2.64B raised creates preference overhang that would need to absorb; (3) continued private growth with further late-stage rounds. The Series F-Prime ($317M led by Centricus/The Space Between, with new strategic investors including Morgan Health/JPMorganChase, GV, Franklin Templeton, and VanEck) suggests the company is actively broadening its institutional investor base, possibly in preparation for a future liquidity event. Key diligence gaps include the absence of consolidated financial statements, unknown preference overhang from $2.64B raised, and no publicly disclosed Series F valuation. Thesis-break triggers include: (1) MLR returning above 89% for two consecutive quarters, (2) CMS announcing >3% revenue cuts for the 2027 plan year, (3) loss of 4-star contracts covering more than 20% of membership, or (4) a down-round financing. [CV033, CV034, CV035, CV036, CV037, CV038]

8.5 Exhibits